Related Experiment Videos
[Drug-induced lupus erythematosus]
F Atzeni1, M G Marrazza, P Sarzi-Puttini
1Unità Operativa di Reumatologia, Università Ospedale L. Sacco, Milano, Italia. atzenifabiola@hotmail.com
Reumatismo
|September 27, 2003
Summary
Drug-induced lupus erythematosus (DILE) is a condition mimicking idiopathic systemic lupus erythematosus (SLE), triggered by over 80 medications. Early recognition and drug cessation lead to symptom resolution.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Context:
- Drug-induced lupus erythematosus (DILE) presents with symptoms and laboratory findings similar to idiopathic systemic lupus erythematosus (SLE).
- Over 80 drugs have been identified as potential causes of DILE, with new agents continually being implicated.
- The condition, also known as lupus-like syndrome or drug-related lupus, has a growing list of associated medications.
Purpose:
- To review the characteristics, implicated medications, and clinical significance of drug-induced lupus erythematosus (DILE).
- To highlight the importance of recognizing DILE for timely intervention and patient management.
Summary:
- DILE shares clinical and serological features with idiopathic SLE, including arthralgia, myalgia, pleurisy, rash, fever, and antinuclear antibodies.
- Historically, sulfadiazine and hydralazine were among the first drugs linked to DILE.
- Medications causing DILE can be broadly categorized, though the extensive and expanding list necessitates ongoing vigilance.
Impact:
- Prompt identification of DILE is crucial as the syndrome typically resolves within weeks of discontinuing the causative agent.
- Understanding the expanding list of drugs associated with DILE aids clinicians in differential diagnosis and patient counseling.